Meeting
2018 ASCO Annual Meeting
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
Authors
Valerie W. Rusch
Memorial Sloan Kettering Cancer Center, New York, NY
Valerie W. Rusch , Jamie E. Chaft , Bruce Johnson , Ignacio Ivan Wistuba , Mark G. Kris , Jay M. Lee , Paul A. Bunn Jr., David J. Kwiatkowski , Karen L. Reckamp , David J Finley , Eric B. Haura , Saiama Naheed Waqar , Robert Charles Doebele , Edward B. Garon , Justin Blasberg , Alan Nicholas , Katja Schulze , See-Chun Phan , Mayank Gandhi , David Paul Carbone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02927301
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8541)
DOI
10.1200/JCO.2018.36.15_suppl.8541
Abstract #
8541
Poster Bd #
147
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.
First Author: Filiz Oezkan
Poster
2017 ASCO Annual Meeting
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
First Author: Dwight Hall Owen
Poster
2018 ASCO Annual Meeting
Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
First Author: Helen J. Ross
Poster
2024 ASCO Annual Meeting
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.
First Author: Yana Qi